Print
Email
Print Edition Stories
ImmunoGen Inc. has begun a clinical trial of its small-cell lung cancer treatment, IMGN901.
The randomized Phase 1/2 trial is expected to test the effects of using IMGN901 in combination with carboplatin plus etoposide (C/E) – the current first-line treatment available. The trial will compare the combination treatment and the treatment of C/E alone. The FDA has granted orphan drug status in the U.S. to IMGN901 for its use in treating small-cell lung cancer and Merkel cell carcinoma.
In a press release today, Waltham-based ImmunoGen noted its goal endpoint for the trial – progression-free survival.
Last month, ImmunoGen (Nasdaq: IMGN) agreed to work with Novartis on targeted anticancer therapeutics developed using ImmunoGen’s Targeted Antibody Payload (TAP) technology, in a deal potentially worth nearly $250 million – and potentially much more.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
